Viewing Study NCT07388550


Ignite Creation Date: 2026-03-26 @ 3:15 PM
Ignite Modification Date: 2026-03-30 @ 2:46 AM
Study NCT ID: NCT07388550
Status: NOT_YET_RECRUITING
Last Update Posted: 2026-03-25
First Post: 2026-02-04
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Post-Acute COVID-19 Syndrome View
Keywords:

Keywords

Keyword Brief Keyword Text View
None PASC View
None Long Covid View
None COVID View
None COVID-19 View
None Postacute Sequelae of COVID View